For example, SMARCA4 loss shows synthetic lethality with CDK4/6 inhibition in NSCLC [38] and causes a long-lasting major response after pembrolizumab treatment in thoracic malignant rhabdoid-like tumors [39]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.